Fol. Biol. 2015, 61, 110-115
https://doi.org/10.14712/fb2015061030110
Effect of Asenapine on the Activity of Hypocretin Neurons in Normal and Unpredictable Mild Stress Preconditioned Rats
References
1. , D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., Weiden, P. J. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156, 1686-1696.
<https://doi.org/10.1176/ajp.156.11.1686>
2. , D. B., Casey, D. E. (2001) Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry 62, 22-31.
3. , J., Baratta, M. V., Paul, E., Bland, S. T., Watkins, L. R., Maier, S. E. (2005) Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat. Neurosci. 8, 365-371.
<https://doi.org/10.1038/nn1399>
4. , H. N., Procyshyn, R. M., Pang, C. C., Hawkes, E.,Wong, D., Jin, C. H., Honer,W. G., Barr, A. M. (2013) Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine. PLoS One 8, 1-13.
<https://doi.org/10.1371/journal.pone.0053459>
5. , Y., Ueta, Y., Yamashita, H., Yamaguchi, H., Matsukura, S., Kangawa, K., Sakurai, T., Yanagisawa, M., Nakazato, M. (1999) Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc. Natl. Acad. Sci. USA 96, 748-753.
<https://doi.org/10.1073/pnas.96.2.748>
6. , R. B., Ghedini, P. C. (2014) Treatment by asenapine for 5 weeks decreases weight and triglycerides levels of Wistar rats. Schizophr. Res. 154, 124-125.
<https://doi.org/10.1016/j.schres.2014.02.002>
7. , L., Kilduff, T. S., Peyron, C., Gao, X., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L., Gautvik, V. T., Bartlett, F. S., Frankel, W. N., van den Pol, A. N., Bloom, F. E., Gautvik, K. M., Sutcliffe, J. G. (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA 95, 322-327.
<https://doi.org/10.1073/pnas.95.1.322>
8. , M., Faull, R. (1989) The use of c-fos as a metabolic marker in neuronal pathway tracing. J. Neurosci. Methods 29, 261-265.
<https://doi.org/10.1016/0165-0270(89)90150-7>
9. , I. O., Howard, R. S., Kopelman, M. D., Sharief, M. K., Williams, A. J. (2002) The hypocretin/orexin system. J. R. Soc. Med. 95, 227-230.
<https://doi.org/10.1177/014107680209500503>
10. , C. M., Abusnana, S., Sunter, D., Murphy, K. G., Ghatei, M. A., Bloom, S. R. (1999) The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. J. Endocrinol. 160, R7-12.
<https://doi.org/10.1677/joe.0.160r007>
11. , J., Bubser, M., Deutch, A. Y. (2002) Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J. Neurosci. 22, 6742-6746.
<https://doi.org/10.1523/JNEUROSCI.22-15-06742.2002>
12. , A., Forgione, R. N., Morana, B., Maccari, M., Goracci, A., Bossini, L., Pellegrini, F., Cuomo, A., Casamassima, F. (2013) Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin. Pharmacother. 14, 489-504.
<https://doi.org/10.1517/14656566.2013.765859>
13. , J., Varela, L., Skrede, S., Vázquez, M. J., Nogueiras, R., Diéguez, C., Vidal-Puig, A., Steen, V. M., López, M. (2011) Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS One, 6, e20571.
<https://doi.org/10.1371/journal.pone.0020571>
14. , J., Beuckmann, C. T., Nambu,T., Willie, J. T., Chemelli, R. M., Sinton, C. M., Sugiyama, F., Yagami, K., Goto, K., Yanagisawa, M., Sakurai, T. (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30, 345-354.
<https://doi.org/10.1016/S0896-6273(01)00293-8>
15. , M. M., Apergis-Schoute, J., Adamantidis, A., Jensen, L. T., de Lecea, L., Fugger, L., Burdakov, D. (2011) Activation of central orexin/hypocretin neurons by dietary amino acids. Neuron 72, 616-629.
<https://doi.org/10.1016/j.neuron.2011.08.027>
16. , S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., Kissling, W., Stapf, M. P., Lässig, B., Salanti, G., Davis, J. M. (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis. Lancet 382, 951-962.
<https://doi.org/10.1016/S0140-6736(13)60733-3>
17. , X., Johnson, M. S., Smith, D. L., Jr, Li, Y., Kesterson, R. A., Allison, D. B., Nagy, T. R. (2013) Effects of risperidone on energy balance in female C57BL/6J mice. Obesity (Silver Spring) 21, 1850-1857.
<https://doi.org/10.1002/oby.20350>
18. , Z., van Weering, H., Scsukova, S., Mikkelsen, J. D., Kiss, A. (2012) A new approach of light microscopic immunohistochemical triple-staining: combination of Fos labeling with diaminobenzidine-nickel and neuropeptides labeled with Alexa488 and Alexa555 fluorescent dyes. Endocr. Regul. 46, 217-223.
<https://doi.org/10.4149/endo_2012_04_217>
19. , Z., Cernackova, A., Horvathova, L., Osacka, J., Pecenak, J., Kiss, A. (2014) Effect of acute asenapine treatment on Fos expression in the forebrain structures under normal conditions and mild stress preconditioning in the rat. Brain Res. Bull. 108, 60-66.
<https://doi.org/10.1016/j.brainresbull.2014.08.006>
20. , K. D., Beiderbeck, D. I., Lukas, M., Neumann, I. D., Reber, S. O. (2012) Chronic subordinate colony housing (CSC) as a model of chronic psychosocial stress in male rats. PLoS One 7, e52371.
<https://doi.org/10.1371/journal.pone.0052371>
21. Paxinos, G., Watson, C. (2007) The Rat Brain in Stereotaxic Coordinates, compact 6th ed., Academic Press, Sydney.
22. , C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., Kilduff, T. S. (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996-10015.
<https://doi.org/10.1523/JNEUROSCI.18-23-09996.1998>
23. , T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., Arch, J. R., Buckingham, R. E., Haynes, A. C., Carr, S. A., Annan, R. S., McNulty, D. E., Liu, W. S., Terrett, J. A., Elshourbagy, N. A., Bergsma, D. J., Yanagisawa, M. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G proteincoupled receptors that regulate feeding behavior. Cell 92, 573-585.
<https://doi.org/10.1016/S0092-8674(00)80949-6>
24. , M., Walker, G. B., Zorn, S. H., Wong, E. H. (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. 23, 65-73.
<https://doi.org/10.1177/0269881107082944>
25. , S. (2012) Asenapine: a clinical review of a secondgeneration antipsychotic. Clin. Ther. 34, 1023-1040.
<https://doi.org/10.1016/j.clinthera.2012.03.002>
26. , J. G., de Lecea, L. (2000) The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. J. Neurosci. Res. 62, 161-168.
<https://doi.org/10.1002/1097-4547(20001015)62:2<161::AID-JNR1>3.0.CO;2-1>
27. , A., Zhao, J., van Willigenburg, A., Nations, K. R., Mackle, M., Panagides, J. (2011) Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry 11, 101.
<https://doi.org/10.1186/1471-244X-11-101>
28. , D. M., McAskill, R. (2000) Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr. Scand. 101, 416-432.
<https://doi.org/10.1034/j.1600-0447.2000.101006416.x>
29. , T., Mussigbrodt, H. E. (1999) Weight gain: side effect of atypical neuroleptics? J. Clin. Psychopharmacol. 19, 316–321.
<https://doi.org/10.1097/00004714-199908000-00006>
30. , P. (1990) Animal models of depression: an overview. Pharmacol. Therap. 45, 425-455.
<https://doi.org/10.1016/0163-7258(90)90076-E>
